Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of natalizumab in
individuals diagnosed with moderately to severely active Crohn's disease. It is thought that
natalizumab may stop the movement of certain cells, known as white blood cells, into bowel
tissue. These cells are thought to cause damage in the bowel leading to the symptoms of
Crohn's disease.